Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $50.42 Average Target Price from Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been given a consensus rating of “Buy” by the thirteen brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $49.91.

DYN has been the subject of several recent analyst reports. Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Royal Bank of Canada started coverage on shares of Dyne Therapeutics in a report on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Finally, JPMorgan Chase & Co. lowered Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $43.00 to $35.00 in a research report on Thursday, October 24th.

Dyne Therapeutics Trading Down 2.7 %

Shares of DYN opened at $24.76 on Monday. The firm’s fifty day simple moving average is $27.78 and its two-hundred day simple moving average is $34.44. Dyne Therapeutics has a 12 month low of $14.29 and a 12 month high of $47.45. The stock has a market capitalization of $2.52 billion, a P/E ratio of -6.96 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, research analysts predict that Dyne Therapeutics will post -3.45 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, Director Dirk Kersten sold 23,671 shares of Dyne Therapeutics stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total transaction of $836,769.85. Following the sale, the director now directly owns 99,652 shares in the company, valued at approximately $3,522,698.20. This trade represents a 19.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Richard William Scalzo sold 1,455 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the transaction, the senior vice president now directly owns 127,078 shares in the company, valued at approximately $3,573,433.36. This represents a 1.13 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 44,742 shares of company stock valued at $1,443,246. 20.77% of the stock is owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Large investors have recently made changes to their positions in the business. AQR Capital Management LLC grew its position in Dyne Therapeutics by 4.3% during the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock valued at $300,000 after buying an additional 352 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Dyne Therapeutics by 24.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock valued at $123,000 after acquiring an additional 709 shares during the last quarter. KBC Group NV grew its position in shares of Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after acquiring an additional 751 shares during the period. Amalgamated Bank grew its position in shares of Dyne Therapeutics by 39.9% during the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after acquiring an additional 796 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in shares of Dyne Therapeutics during the 3rd quarter worth approximately $34,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.